Search results
Results From The WOW.Com Content Network
In June 2023, Viatris was named to the Forbes Global 2000 list of the world's largest companies. [24] In October 2023, Viatris reached agreements to divest from almost all of its OTC business, its women’s healthcare business, and its India-based active pharmaceutical ingredients business for a total of about $3.6 billion. [25]
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Valeant Pharmaceuticals: Allergan, Inc: 45 58 Valeant Pharmaceuticals and activist investor Bill Ackman offered to buy Botox maker Allergan, proposing a cash-and-stock deal worth about $152.89. [31] 20 2014 Monsanto Company Inc. Syngenta AG: 40 51 Monsanto weighed $40 billion unsolicited bid for Swiss rival, Syngenta aiming to avoid US ...
Dec. 2—Pfizer Inc. is starting to roll out the pharmaceutical company's biggest round of layoffs since 2009, and its Groton laboratories are not immune. Of course, New York-based Pfizer these ...
Donald Trump's Agenda 47 and the Heritage Foundation's Project 2025 provide plenty of clues into what health-care changes may be coming. ... by brand-name pharmaceutical manufacturers, ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The Centers for Medicare and Medicaid Services (CMS) released its first-ever negotiated drug price list Thursday morning to a muted response on Wall Street. But industry and government officials ...
The company expects to be profitable in 2025. [ 2 ] In July 2023 due to a disappointing sales ramp-up of the recently approved sleep drug daridorexant , coupled with disappointing trial results in both clazosentan and lucerestat , Idorsia announced layoffs of up to five hundred staff of its one thousand two hundred total employees, to reduce ...